Related references
Note: Only part of the references are listed.Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
Yuefeng Wang et al.
SCIENTIFIC REPORTS (2017)
Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients
Xiaoyan Li et al.
CLINICA CHIMICA ACTA (2017)
MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma
Zhi-Xia Yue et al.
CANCER CELL INTERNATIONAL (2017)
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project
Daria Thompson et al.
CANCER (2016)
Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples
Yazhen Zhu et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2016)
Neuroblastoma
Katherine K. Matthay et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes
Faizan H. Khan et al.
BMC CANCER (2015)
Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells
Faizan H. Khan et al.
BMC GENOMICS (2015)
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
L. L. Wang et al.
BRITISH JOURNAL OF CANCER (2015)
Droplet digital PCR measurement of HER2 in patients with gastric cancer
H. Kinugasa et al.
BRITISH JOURNAL OF CANCER (2015)
RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes
Faizan H. Khan et al.
ONCOTARGET (2015)
Novel adjuvants from seaweed impede autophagy signaling in therapy-resistant residual pancreatic cancer
Sheeja Aravindan et al.
JOURNAL OF BIOMEDICAL SCIENCE (2015)
A Comparison of Immunohistochemical Assays and FISH in Detecting the ALK Translocation in Diagnostic Histological and Cytological Lung Tumor Material
John Le Quesne et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Current and Future Strategies for Relapsed Neuroblastoma: Challenges on the Road to Precision Therapy
Daniel A. Morgenstern et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2013)
Droplet Digital™ PCR quantitation of HER2 expression in FFPE breast cancer samples
Nicholas J. Heredia et al.
METHODS (2013)
Comparison of IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in 312 Non-Small Cell Lung Cancer Patients in Taiwan
Yi-Cheng Wu et al.
PLOS ONE (2013)
Neuroblastoma and MYCN
Miller Huang et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2013)
New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome
Kristina A. Cole et al.
CLINICAL CANCER RESEARCH (2012)
High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number
Benjamin J. Hindson et al.
ANALYTICAL CHEMISTRY (2011)
Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project
Wendy B. London et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment and Outcomes of Patients With Relapsed, High-Risk Neuroblastoma: Results of German Trials
Thorsten Simon et al.
PEDIATRIC BLOOD & CANCER (2011)
Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century
Malcolm A. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry
Alberto Garaventa et al.
EUROPEAN JOURNAL OF CANCER (2009)
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Disease control intervals in high-risk neuroblastoma
Victor M. Santana et al.
CANCER (2008)
Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma?: A Children's Oncology Group study
Lisa A. Moreau et al.
CLINICAL CANCER RESEARCH (2006)
Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR
J Anderson et al.
PEDIATRIC BLOOD & CANCER (2006)
Identification of MYCN gene amplification in neuroblastoma using chromogenic in situ hybridization (CISH) An alternative and practical method
R Bhargava et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2005)
Factors influencing survival in children with recurrent neuroblastoma
L Lau et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2004)
CDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma -: art. no. 70
QR Chen et al.
BMC GENOMICS (2004)
Automatic quantification of gene amplification in clinical samples by IQ-FISH
R Narath et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2004)
Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma
B Weiss et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2003)
Detection of N-myc amplification in neuroblastomas using Southern blotting on fine needle aspirates
H Barroca et al.
ACTA CYTOLOGICA (2001)
MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN
SL Cohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry - A study of interlaboratory agreement
TW Jacobs et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2000)
Share Paper
